Please check your internet connection and try again.
# Att-drugs
## Overview
Att-drugs is a combination product containing Atropine Sulfate and Diphenoxamine Hydrochloride. Atropine is an anticholinergic agent, and Diphenoxamine is an opioid agonist that acts primarily on the mu-opioid receptors in the myenteric plexus of the intestine.
## Primary Indications
* Symptomatic treatment of diarrhea.
## Adult Dosing
* **Diarrhea:**
* Initial dose: 2 tablets (each tablet contains 0.025 mg atropine sulfate and 2.5 mg diphenoxamide HCl) orally 4 times daily.
* Maintenance dose: 1-2 tablets orally 4 times daily as needed.
* Maximum dose: 8 tablets per day.
## Pediatric Dosing
* Dosing in pediatric patients is not recommended due to the risk of respiratory depression and other central nervous system effects, particularly in younger children. The concentration of diphenoxamide HCl in the standard formulation is too high for safe pediatric use.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but reduced doses may be necessary due to impaired metabolism.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established.
## Contraindications
* Severe hepatic disease.
* Obstructive jaundice.
* Diarrhea caused by *Clostridium difficile* (associated with antibiotic use).
* Diarrhea associated with infections where inhibition of peristalsis may be detrimental (e.g., certain bacterial infections).
* Hypersensitivity to atropine or diphenoxamide.
* Children under 2 years of age (absolute contraindication due to risk of fatal respiratory depression).
## Adverse Effects
* **Common:** Constipation, dry mouth, dizziness, drowsiness, nausea, vomiting, abdominal discomfort.
* **Serious:** Respiratory depression, paralytic ileus, urinary retention, blurred vision, fever, severe abdominal distension, toxic megacolon. Anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation) are also dose-related.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, benzodiazepines, opioids, sedatives/hypnotics):** Increased risk of respiratory depression and sedation.
* **MAO Inhibitors:** May potentiate hypertensive crisis. Avoid use.
* **Anticholinergic Agents:** Additive anticholinergic effects.
## Monitoring
* Frequency and consistency of stools.
* Signs of abdominal distension or constipation.
* Signs of respiratory depression or CNS effects (especially in patients with risk factors).
* Hydration status.
## Clinical Pearls
* Att-drugs should be used cautiously and for the shortest duration necessary.
* The atropine component is present in subtherapeutic amounts to discourage abuse by producing unpleasant anticholinergic side effects if taken in excessive doses.
* Discontinue use if symptoms do not improve within 48 hours or if constipation, abdominal distension, or signs of CNS/respiratory depression occur.
* Avoid use in patients with inflammatory bowel disease where increased colonic transit time may be dangerous.
***
*This information is for educational purposes only and does not substitute professional medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information before making any treatment decisions.*
